Kelly C. Rogers, Pharm.D., BCCP, FCCP, FACC

Department of Clinical Pharmacy and Translational Science

MEMPHIS TN 381632198
Tel: (901) 448-3702


  • None, University of Virginia Health Sciences Center, Charlottesville, VA, PGY-1 Residency
  • Pharm.D., University of TN COP, Memphis, Pharmacy
  • None, University of Memphis, Memphis, Pre-Pharmacy


  1. Rogers KC, de Denus S, Finks SW, Spinler SA.. Acute Coronary Syndromes. In: DiPiro J, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York: McGraw-Hill Companies; 2017:165-192...
  2. Rogers KC.. Stable Atherosclerotic Disease.  In: Baker WL, Beavers C, Bolesta S, et al., eds. Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy, 2018:127-158...
  3. Shelton CM, Rogers KC. Monitoring Drug Therapy. In: Nemire RE, Kier K, Assa-Eley M, editors. Pharmacy Student Survival Guide. 3rd ed. New York: McGraw-Hill Companies; 2014:128-156...
  4. Oliphant CS, Finks SW. Rogers KC. Ischemic Heart Disease and Acute Coronary Syndrome In: Chyka PA, Franks AS, Waddell JA, Boucher BA, editors. The APhA's Complete Review for Pharmacy.  12th ed. Washington, D.C.:  American Pharmacists Association; 2017:289-320...
  5. Rogers KC, Parker RB. Acute Myocardial Infarction. In: Schwinghammer TL, Koehler JM, Borchert JS, Park S, Slain DS, eds. Pharmacotherapy Casebook: A Patient-Focused Approach, 10th ed. New York: McGraw-Hill Companies; 2017:67-70...
  6. Rogers KC, Finks SW, Spinler S. Acute Coronary Syndromes. In: Chisholm-Burns MA, Schwinghammer TL Wells BG, et al, eds. Pharmacotherapy: Principles and Practice. 5th ed. New York: McGraw-Hill Companies...
  7. Rogers KC, de Denus S, Finks SW. Acute Coronary Syndromes. In: Chisholm-Burns MA, Schwinghammer TL Wells BG, et al, eds. Pharmacotherapy: Principles and Practice. 4th ed. New York: McGraw-Hill Companies; 2016:111-136...
  8. Kessler, SG, Gillion, AR, Pattanaik, D, Rogers, KC. Nitrate allergy and desensitization in a patient with refractory angina. J Allergy Clin Immunol Pract, 2018.
  9. Rogers, KC, Finks, SW. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Am J Med, 2018.
  10. Shah, R, Matin, K, Rogers, KC, Rao, SV. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv, 90 (2), 196-204, 2017.
  11. Finks, SW, Rogers, KC. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. Am J Med, 130 (5), e195-e197, 2017.
  12. Rogers, KC, Shelton, MP, Finks, SW. Reversal Agents for Direct Oral Anticoagulants: Understanding New and Upcoming Options. Cardiol Rev, 24 (6), 310-315, 2016.
  13. Shah, R, Rogers, KC, Ahmed, AJ, King, BJ, Rao, SV. Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv, 9 (13), 1313-20, 2016.
  14. Shah, R, Rogers, KC, Matin, K, Askari, R, Rao, SV. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. Am Heart J, 171 (1), 14-24, 2016.
  15. Rogers, KC, Oliphant, CS, Finks, SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs, 75 (4), 377-95, 2015.
  16. Shah, R, Slomka, T, Rogers, KC. Dual antiplatelet treatment after stenting. Lancet, 385 (9965), 326, 2015.
  17. Finks, SW, Airee, A, Chow, SL, Macaulay, TE, Moranville, MP, Rogers, KC, Trujillo, TC. Key articles of dietary interventions that influence cardiovascular mortality. Pharmacotherapy, 32 (4), e54-87, 2012.
  18. Finks, SW, Rogers, KC, Manguso, AH. Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement. Int J Pharm Pract, 19 (4), 281-6, 2011.
  19. Cheng JWM, Dopp AL, Kalus JL, Rogers KC, Sanoski CA, White CM. Key articles and guidelines in the management of arrhythmias, 2004-2010.. Pharmacotherapy, 1 (31), 1e-32e, 2011.
  20. Goddard, KB, Eppert, HD, Underwood, EL, McLean, KM, Finks, SW, Rogers, KC. Basic life support and cardiopulmonary resuscitation training for pharmacy students and the community by a pharmacy student committee. Am J Pharm Educ, 74 (6), 100, 2010.
  21. Finks, SW, Oliphant, CS, Manguso, AH, Rogers, KC, Bridges, G, Haidar, CE, Lee, KR, Lee, M, Lobo, B, May, AM, Reaves, A, Swanson, JM, Swims, M, Vinson, J, Yates, ME. Activities of Memphis-area hospitals to meet National Patient Safety Goals for warfarin therapy. Am J Health Syst Pharm, 66 (24), 2179-88, 2009.
  22. Rogers, KC, Finks, SW. Job sharing for women pharmacists in academia. Am J Pharm Educ, 73 (7), 135, 2009.
  23. Czosnowski, QA, Finks, SW, Rogers, KC. Bivalirudin for patients with heparin-induced thrombocytopenia undergoing cardiovascular surgery. Ann Pharmacother, 42 (9), 1304-9, 2008.
  24. Finks, SW, Rogers, KC. Job-sharing. Drs. Finks and Rogers interviewed by Kate Traynor, M.S., AJHP News writer. Am J Health Syst Pharm, 65 (1), 69-72, 2008.
  25. Rogers, KC, Wolfe, DA. Ibutilide: a class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter. J Emerg Med, 20 (1), 67-71, 2001.
  26. Rogers, KC, Wolfe, DA. Amiodarone-induced blue-gray syndrome. Ann Pharmacother, 34 (9), 1075, 2000.